Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/ijms22041623
Keywords
IBD; microbiota– gut– brain axis; dysbiosis; microbiota targeting therapies; antibiotics; probiotics; prebiotics; fecal transplant therapy
Funding
- University of Insubria
- University of Pavia
Ask authors/readers for more resources
This article discusses the role of the microbiota-gut-brain axis in the pathogenesis of Inflammatory Bowel Disease (IBD) and the impact of microbial-derived metabolites on the development of IBD-related symptoms. It points out that mood disorders and heightened stress responses may affect the severity of IBD.
The complex bidirectional communication system existing between the gastrointestinal tract and the brain initially termed the gut-brain axis and renamed the microbiota-gut-brain axis, considering the pivotal role of gut microbiota in sustaining local and systemic homeostasis, has a fundamental role in the pathogenesis of Inflammatory Bowel Disease (IBD). The integration of signals deriving from the host neuronal, immune, and endocrine systems with signals deriving from the microbiota may influence the development of the local inflammatory injury and impacts also more distal brain regions, underlying the psychophysiological vulnerability of IBD patients. Mood disorders and increased response to stress are frequently associated with IBD and may affect the disease recurrence and severity, thus requiring an appropriate therapeutic approach in addition to conventional anti-inflammatory treatments. This review highlights the more recent evidence suggesting that alterations of the microbiota-gut-brain bidirectional communication axis may concur to IBD pathogenesis and sustain the development of both local and CNS symptoms. The participation of the main microbial-derived metabolites, also defined as postbiotics, such as bile acids, short-chain fatty acids, and tryptophan metabolites in the development of IBD-associated gut and brain dysfunction will be discussed. The last section covers a critical evaluation of the main clinical evidence pointing to the microbiome-based therapeutic approaches for the treatment of IBD-related gastrointestinal and neuropsychiatric symptoms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available